Mr. Wang has 25 years of investment banking experience and is widely recognized as one of the most influential figures and pioneers in China's investment banking industry. He founded CEC Capital Group (formerly known as China eCapital Group) in 2000 and is now chairman and CEO of the firm. Under his leadership, CEC Capital, which has closed over 500 transactions with total deal value exceeding RMB500 billion, has emerged as a leading private investment bank and asset management firm with a core focus on the TMT, consumer and healthcare sectors. 

Mr. Wang started his investment banking career at Goldman Sachs in 1994. Prior to founding CEC Capital, he had spent the previous three years with the Global M&A Group of JP Morgan, where he was responsible for developing and executing a number of large M&A transactions in the Asia-Pacific region. Mr. Wang has a bachelor degree in economics from Harvard College and an MBA from Harvard Business School. He has published extensively in leading Chinese financial press.

Ms. Hong is a founding partner for CEC Capital Group, and leads the healthcare industry group. Under her guidance, CEC Capital has emerged as a leader in the healthcare industry with the largest specialized team of over 50 dedicated healthcare bankers, covering pharma/biotech, medical device, services, digital healthcare, and synthetic biology sectors. CEC works with leading China healthcare players and also has a strong cross-border practice.

Prior to joining CEC Capital, Ms. Hong was with Accenture Strategic Services (formerly Andersen Consulting) in San Francisco. Before receiving her MBA, Ms. Hong worked as an engineer for Merck and worked on several significant projects, including a humanitarian technology transfer of a Recombinant Hepatitis B vaccine to China, and the launch of Crixivan, a protease inhibitor for HIV. 

Ms. Hong has both her MBA and BS in Mechanical Engineering from UC Berkeley.

Mr. Li Gang joined CEC Capital in 2016 and is currently a Partner and Head of Healthcare team of CEC Capital. Mr. Li focuses on serving the world's leading healthcare companies and has rich operational experience and industry insights, especially in investment, financing and M&A of leading companies in Biotech, Life sciences, Medtech, healthcare services, and big data AI industries. Mr. Li has provided professional investment banking services to many outstanding companies in the healthcare industry, including GE, Sanofi, bioMérieux, Google Life Sciences, Fresenius, WuXi App Tec, Haier Group, Arrail Dental, Sanbo Brain Hospital and Bluesail Medical.

Mr. Li once served as the Senior Vice President at CITIC Securities and participated in various projects covering refinancing, overseas M&A, asset restructuring and financial advising services. During his tenure in CITIC Securities, he also directly promoted and participated in the establishment and implementation of several fund and asset management programs.

As a veteran investor, Mr. Wang has rich experience in domestic and foreign investment, management consulting and business operations.  

His career began at the US-based General Mills, where he participated in and completed the largest M&A transactions in the company’s history.  After returning to China, he worked at Roland Berger as a senior consultant in consumer goods, healthcare and other industries.  In 2010, Mr. Wang joined CEC Capital and during the four years spent here, he completed financing and M&A transactions worth over RMB 10 billion before leaving as the senior director of M&A.  In 2014, he joined the Fosun Group where he served as the Executive Director of International Development Department and China Momentum Fund and led a number of investments in Infront Sports & Media, DTZ Zadelhoff, and other companies.  In 2016, he returned to CEC and as a founder of the RMB fund, where he serves as a fund partner and member of the Investment Committee.

Mr. Wang holds an MBA from Oxford University and a BS degree in Management from Ohio State University.

Mr. Li Jin is a Partner at CEC Capital and Head of the Medtech Division. Since joining CEC Capital in 2020, Mr. Li has led the team to complete numerous financing transactions in Medtech, including notable deals such as WuXi Diagnostics, GenomePrecision Tech, b-ONE, NuProbe, Visionmedicals, and UnionStrong Tech. Before joining CEC Capital, he worked for BGI Co-win, focusing on private equity investments.